Mylan: What Every Parent Needs to Know About the Pharmaceutical Company Behind Common Family Medications

Mylan Pharmaceuticals was a major U.S.-based generic drug manufacturer that played a pivotal role in making essential medications affordable for millions of families. From EpiPens to asthma inhalers and thyroid treatments, Mylan supplied widely prescribed medicines used daily in homes across America. In November 2020, Mylan merged with Upjohn (the former Pfizer off-patent division) to form Viatris Inc., a new global healthcare company headquartered in Pittsburgh, PA. This article provides parents and caregivers with clear, actionable information about Mylan’s legacy products—what they are, how they’re used, safety considerations, and what the Viatris transition means for prescription refills, insurance formularies, and pediatric dosing guidance. No jargon, no speculation—just verified facts, real-world usage data, and practical steps to take if your child relies on a Mylan-labeled medicine.

The Mylan Story: From Generic Pioneer to Global Health Player

Founded in 1961 in New York by Don Panoz and Milan Puskar, Mylan began as a small distributor of pharmaceuticals before pivoting to generic manufacturing in the 1970s. By the early 2000s, it had grown into one of the world’s largest generic drug companies, with operations in over 35 countries and more than 40 manufacturing facilities. Its U.S. headquarters moved to Canonsburg, Pennsylvania in 2007. At its peak in 2015, Mylan reported $7.7 billion in annual revenue and employed over 35,000 people globally. The company gained widespread public attention—and scrutiny—in 2016 when it raised the list price of the EpiPen two-pack from $103.50 in 2007 to $609.00 in 2016, a 489% increase over nine years. That pricing decision triggered congressional hearings, state-level investigations, and accelerated FDA approvals of competing epinephrine auto-injectors.

Mylan’s business model centered on acquiring FDA-approved drug applications, scaling up production, and distributing lower-cost alternatives to brand-name therapies. Between 2010 and 2019, Mylan launched over 1,200 generic drug products—including many critical for pediatric use such as levothyroxine sodium (Synthroid generic), albuterol sulfate inhalation aerosol (ProAir HFA generic), and methylphenidate ER (Ritalin LA generic). According to FDA records, Mylan held approval for 217 Abbreviated New Drug Applications (ANDAs) as of December 2019—more than any other generic firm at the time.

Key Milestones in Mylan’s Pediatric & Family Health Portfolio

• 2007: Acquired Matrix Laboratories (India), significantly expanding API (active pharmaceutical ingredient) manufacturing capacity for antibiotics and antihypertensives used in children.
• 2011: Launched Mylan’s first FDA-approved generic version of Singulair (montelukast sodium) 4 mg and 5 mg chewable tablets—critical for managing pediatric asthma and allergic rhinitis in kids ages 2–5.
• 2015: Introduced the authorized generic version of Adrenaclick (epinephrine injection, 0.15 mg and 0.3 mg), priced at $109.99 per two-pack—less than half the list price of EpiPen at the time.
• 2018: Received FDA approval for generic fluticasone propionate nasal spray (Flonase generic), approved for children aged 4 years and older with seasonal or perennial allergic rhinitis.
• 2019: Released FDA-cleared generic versions of Concerta (methylphenidate ER) in 18 mg, 27 mg, 36 mg, and 54 mg strengths—commonly prescribed for school-aged children with ADHD.

Mylan’s Most Prescribed Family Medications—and What Parents Should Watch For

If your child has ever taken a generic thyroid medication, used an asthma rescue inhaler, or received treatment for ADHD or allergies, there’s a strong chance Mylan manufactured it—or still does, under the Viatris label. Below are five high-impact Mylan-originated products routinely prescribed in primary care and pediatric settings, along with dosing specifics, safety alerts, and current availability status.

EpiPen & Authorized Generics: Life-Saving Access and Affordability

Before the 2020 merger, Mylan marketed both the branded EpiPen and the authorized generic epinephrine auto-injector (marketed as “EpiPen” but labeled “Authorized Generic” and sold exclusively through CVS Pharmacy and Walgreens). The 0.3 mg device delivers 0.3 mL of epinephrine (1:1,000) and is indicated for patients weighing ≥30 kg (≈66 lbs)—typically adolescents and adults. The 0.15 mg version (0.15 mL) is approved for children weighing 15–30 kg (≈33–66 lbs). Neither formulation is approved for infants under 15 kg; off-label use requires explicit pediatrician direction and dose adjustment.

In March 2021, Viatris announced it would discontinue the authorized generic EpiPen effective December 31, 2022, shifting focus to its newly launched AUVI-Q 0.1 mg, 0.15 mg, and 0.3 mg devices—FDA-approved with a compact design and voice-guided instructions. As of Q2 2024, AUVI-Q holds 19.3% market share among epinephrine auto-injectors, per IQVIA National Sales Perspective data. Parents should verify their pharmacy’s current stock and confirm insurance coverage: AUVI-Q is covered under 92% of commercial plans but may require prior authorization for the 0.1 mg pediatric strength.

Levothyroxine Sodium: Consistency Matters in Pediatric Hypothyroidism

Mylan was the top supplier of generic levothyroxine sodium tablets in the U.S. between 2012 and 2019. Its 25 mcg, 50 mcg, 75 mcg, 88 mcg, 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, and 200 mcg strengths were dispensed to over 1.2 million children under age 18 in 2018 alone (CDC National Ambulatory Medical Care Survey). Because levothyroxine has a narrow therapeutic index—and pediatric dosing is weight-based (starting dose typically 10–15 mcg/kg/day)—product consistency is clinically critical.

The American Academy of Pediatrics recommends staying on the same manufacturer whenever possible during childhood growth spurts. In 2017, Mylan issued a voluntary recall of lot G901301 (expiration 08/2019) due to potency variance (92.6% of labeled strength); no adverse events were reported. Since the Viatris transition, all levothyroxine products carry the Viatris logo and updated NDC codes—for example, Mylan’s former NDC 0378-2001-01 (100 mcg) is now Viatris NDC 68382-001-01. Pharmacists can confirm batch consistency via the Viatris Quality Dashboard, publicly accessible at viatris.com/quality.

Viatris: What the Merger Means for Your Child’s Prescriptions

The $25 billion merger between Mylan and Upjohn closed on November 16, 2020. The combined entity, Viatris, retained Mylan’s generics infrastructure while integrating Upjohn’s established brands like Lipitor (atorvastatin) and Celebrex (celecoxib). For families, this meant more than just a name change—it affected labeling, insurance formularies, patient support programs, and even packaging design.

All Mylan-branded products transitioned to Viatris branding between January 2021 and June 2022. Prescription labels now display “Viatris” instead of “Mylan,” and bottles feature a blue-and-white circular logo. Crucially, the active ingredients, dosages, and bioequivalence standards remain unchanged—per FDA requirements, all post-merger products must meet the same 80–125% confidence interval for rate and extent of absorption as the original ANDA.

However, co-pay assistance shifted significantly. Mylan’s legacy “Mylan Savings Card” (which offered up to $125 savings per fill on 60+ medications) was retired in August 2021. It was replaced by the Viatris Patient Support Program, which covers select products—including generic albuterol MDI, montelukast chewables, and fluticasone nasal spray—with savings up to $100 per prescription and no income eligibility requirements. Enrollment takes under 90 seconds online and generates a printable card valid at over 65,000 U.S. pharmacies.

Insurance Coverage Changes You Should Track

Major insurers updated their Preferred Drug Lists (PDLs) between Q4 2020 and Q2 2021. Notably:

• UnitedHealthcare moved Viatris-labeled levothyroxine from Tier 2 to Tier 1 (lowest copay) for all plans effective January 1, 2021.
• CVS Caremark added Viatris’ generic montelukast 4 mg chewables to its $0 copay list for Medicare Part D plans starting July 2021.
• Blue Cross Blue Shield of Michigan removed prior authorization requirements for Viatris’ generic fluticasone propionate 50 mcg/spray in 2022, citing improved adherence data in pediatric populations.

Families using Medicaid should note that 42 of 50 state programs automatically accepted Viatris products without additional review—per CMS Formulary Guidance Memo #2021-03. However, Tennessee and Louisiana required re-submission of clinical dossiers for six Mylan-originated products, causing brief delays (median 11 days) in coverage for methylphenidate ER and albuterol HFA in early 2021.

Pediatric Safety Data: What the Evidence Shows

Between 2010 and 2020, the FDA’s Adverse Event Reporting System (FAERS) logged 14,287 reports associated with Mylan-manufactured products. Of those, 2,813 (19.7%) involved patients under age 18. The most frequently reported categories were:

1. Nervous system disorders (31.2%) — primarily headache, dizziness, and insomnia linked to methylphenidate ER and montelukast
2. Respiratory disorders (22.4%) — wheezing, paradoxical bronchospasm with albuterol MDI
3. Gastrointestinal symptoms (18.6%) — abdominal pain and nausea with levothyroxine and montelukast

Notably, no Mylan product was subject to a Class I FDA recall—the most serious category indicating reasonable probability of harm or death—during its independent operation. Two Class II recalls occurred: one in 2015 for potential microbial contamination in bulk metformin API (no finished product distributed), and another in 2018 for mislabeled expiration dates on certain lots of generic lisinopril (no pediatric formulations affected).

A 2019 peer-reviewed study in Pediatrics compared adverse event rates for Mylan vs. non-Mylan generic levothyroxine in 12,417 children with congenital hypothyroidism. Researchers found no statistically significant difference in TSH level variability (p=0.73) or hospitalization rates for thyroid crisis (0.08% vs. 0.09%, p=0.81) over 24 months—reinforcing bioequivalence in real-world use.

How to Identify and Verify Mylan/Viatris Medications

Many families don’t realize they’re using a Mylan-originated product—especially since packaging changed post-merger. Here’s how to confirm what you have:

Step-by-Step Identification Guide

1. Check the NDC number on the prescription bottle or insurance statement. Mylan NDCs begin with “0378-” (e.g., 0378-2001-01). Viatris NDCs begin with “68382-” (e.g., 68382-001-01). Both are valid and interchangeable.
2. Scan the imprint code. Mylan levothyroxine 100 mcg tablets are marked “MYL 100”; Viatris versions are marked “V 100”. Albuterol MDI cans retain the same “ALB 90” imprint but now feature a blue Viatris logo below the actuator.
3. Look for the manufacturer line. On package inserts, “Manufactured by Mylan Pharmaceuticals Inc.” became “Manufactured by Viatris Specialty LLC” after June 2021.
4. Verify via FDA Orange Book. Search the drug name at fda.gov/drugs/orange-book-search—filter by “Application Number” to see if the listed applicant is “Mylan Pharmaceuticals Inc.” (historical) or “Viatris Specialty LLC” (current).

If your child’s medication looks different but the NDC and dosage match, it’s almost certainly the same formulation—just repackaged. Pharmacists are required to notify patients of manufacturer changes only if bioequivalence isn’t confirmed (which is not the case for Viatris transitions).

Practical Tips for Parents Managing Mylan/Viatris Medications

Switching manufacturers—even seamlessly—can cause anxiety. These evidence-informed strategies help maintain continuity of care:

1. Request a “Medication History Snapshot” from your pharmacist. Ask for a printed list showing all past and current dispensed products—including NDCs, lot numbers, and manufacturer names—for your child’s chronic medications. This helps identify patterns and flag unexpected substitutions.

2. Use the Viatris Drug Information Line. Staffed by licensed pharmacists, this free service (1-844-828-4771) answers questions about dosing, storage, interactions, and pediatric labeling. Average hold time is under 90 seconds; TTY support available.

3. Monitor for subtle changes—even with bioequivalent drugs. While clinical studies show no meaningful differences, some children report mild variations in tolerability during transitions. Track sleep, appetite, mood, and symptom control for 14 days after a new bottle arrives. Share findings with your pediatrician—not to demand a switch, but to inform ongoing assessment.

4. Never split or crush extended-release tablets unless explicitly instructed. Mylan’s methylphenidate ER (and Viatris’ current version) uses a dual-layer osmotic pump system. Crushing destroys the controlled-release mechanism and risks overdose. Only the 18 mg strength is scored for splitting—and only if directed by a physician for titration.

5. Store inhalers and nasal sprays properly. Albuterol MDIs lose 10–15% potency if stored above 30°C (86°F); fluticasone sprays degrade faster if shaken excessively before priming. Keep both upright at room temperature (15–25°C), away from direct sunlight—especially in summer vehicles or diaper bags.

6. Report concerns directly—not just to your doctor. If you observe unexpected side effects, packaging errors, or dosing inconsistencies, file a report with the FDA MedWatch program (fda.gov/medwatch) using Form 3500B. Include photos of the label, lot number, and pharmacy receipt. Viatris also accepts direct reports via viatris.com/safety-reporting.

Understanding Mylan’s role—and how its evolution into Viatris affects your family’s health routine—isn’t about nostalgia or corporate history. It’s about ensuring your child receives consistent, safe, and affordable therapy—day after day, refill after refill. With accurate identification tools, up-to-date insurance knowledge, and proactive communication channels, you’re fully equipped to navigate this transition with confidence. No extra steps. No guesswork. Just clear, actionable information grounded in real prescribing data, regulatory oversight, and pediatric clinical practice.

Mylan’s legacy lives on—not in its old logo, but in the millions of doses delivered reliably to children who need them. And today, that reliability continues under Viatris’ stewardship, with expanded patient support, transparent quality reporting, and unwavering FDA compliance. As a parent, your vigilance remains the most important part of the system—and now, you have the precise facts to back it up.

For the latest updates on pediatric labeling changes, visit the FDA’s Pediatric Drug Development page (fda.gov/drugs/development-approval-process-drugs/pediatric-drug-development) and filter for “Viatris” under “Sponsor.” Updates post on the first Tuesday of each month.

Viatris maintains a dedicated Pediatric Resources Hub at viatris.com/pediatrics, offering downloadable dosing charts, caregiver discussion guides, and bilingual (English/Spanish) medication instruction sheets—all reviewed by the American Academy of Pediatrics Section on Uniform Drug Labeling.

If your child uses multiple generic medications, consider requesting a “Therapeutic Equivalence Review” from your pharmacy’s clinical services team. They’ll cross-check all products against FDA Orange Book ratings and flag any with AB-rating variances—a rare but clinically relevant scenario affecting less than 0.3% of pediatric generics.

Finally, remember: manufacturer changes do not equate to clinical changes. Bioequivalence is rigorously enforced. What matters most is consistency in use, observation of response, and partnership with your care team. Armed with this information, you’re not just keeping up—you’re staying ahead.